# Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

> **NCT02211755** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- Neoplasms
- Myelodysplastic Syndromes
- Lymphomas

## Interventions

- **DRUG:** Bortezomib plus Clofarabine

## Key facts

- **NCT ID:** NCT02211755
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-06
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-08-15
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211755, "Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02211755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*